T-ALL relapsing as AML?
ctnebe (ctnebe@t-online.de)
Sun, 18 May 97 12:31 +0100
Dear Anna,
The original diagnosis was obviously a T-ALL. CD1 and other myeloid marker
were probably negative. The leukemia showed a partial tendency of maturation.
At time of relapse there might be a selection (caused by therapy) of the most
immature cell close to the branching cell of myelo- and lymphopoiesis. The
alternative explanation is the occurance of a new chromosomal abberation under
therapy. The first theory (selection) is more common in AML, the latter I
prefer. Cytogenetics should provide the answer.
AML should be myeloperoxidase positive (+ CD117, CD33 or CDw65) and a secondary,
therapy induced AML should appear later after end of therapy.
Best regards
Thomas Nebe
Klinikum Mannheim
CD-ROM Vol 3 was produced by Monica M. Shively and other staff at the
Purdue University Cytometry Laboratories and distributed free of charge
as an educational service to the cytometry community.
If you have any comments please direct them to
Dr. J. Paul Robinson, Professor & Director,
PUCL, Purdue University, West Lafayette, IN 47907.
Phone: (765)-494-0757;
FAX(765) 494-0517;
Web
http://www.cyto.purdue.edu
, EMAIL
cdrom3@flowcyt.cyto.purdue.edu
